LSPR

Larkspur Health Acquisition Corp

A special purpose acquisition company, or "blank-check" company, formed in 2021 to find and merge with a private biotechnology business — the kind of shell that raises cash from investors but makes no products of its own. Sponsored by Larkspur Health LLC and led by CEO Daniel O'Connor, it went public in December 2021, and in December 2022 completed its merger with drug developer ZyVersa Therapeutics, with the combined company listing on Nasdaq under the ticker ZVSA.

Class A Common Stock — Acquired by ZyVersa Therapeutics (ZVSA) in December 2022

No filing summaries or text available for this security.